Trial Search Results
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: Funded by Toyo Shinyaku Co Ltd
Stanford Investigator(s):
Intervention(s):
- Drug: Pine Bark Extract (Flavangenol®)
Phase:
N/A
Eligibility
Inclusion Criteria:
- Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) <
100 mmHg
- Body mass index (BMI) 25.0-34.9
- Triglycerides (TG) < 450 mg/dL
- Low Density Lipoprotein (LDL) < 200 mg/dL
- Fasting blood glucose (FBG) < 126 mg/dL
Exclusion Criteria:
- DBP > 95 mmHg
- LDL > 170 mg/dL
- TG > 300 mg/dL
- FBG > 110 mg/dL
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Rebbeca Drieling
6507236528